Clinical Trial Update: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports Phase 2 and Phase 3 studies of masitinib in combination with riluzole for ALS; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Masitinib (masitinib)
• Riluzole (riluzole)

Snippet

Sponsor: AB Science | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 2, Phase 3 | Status: COMPLETED